The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BAX | -35.91% | -68.45% | -20.6% | +10,437% |
| S&P | +14.5% | +93.32% | +14.09% | +6,871% |
Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.81B | -26.3% |
| Gross Profit | $968.00M | -30.3% |
| Gross Margin | 34.45% | -2.0% |
| Market Cap | $15.54B | -8.8% |
| Market Cap / Employee | $0.41M | 0.0% |
| Employees | 38K | -36.7% |
| Net Income | $122.00M | 139.2% |
| EBITDA | $452.00M | -28.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.69B | -19.5% |
| Accounts Receivable | $1.83B | -32.1% |
| Inventory | 2.4K | -20.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $9.72B | -10.6% |
| Short Term Debt | $8.00M | -99.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -1.04% | -0.5% |
| Return On Invested Capital | -0.25% | -1.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $77.00M | 7800.0% |
| Operating Free Cash Flow | $217.00M | 88.7% |
| Metric | Q3 2024 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 165.59 | - | |||
| Price to Book | 2.53 | 1.89 | 2.51 | 2.19 | 5.20% |
| Price to Sales | 1.39 | 1.16 | 1.48 | 1.43 | 25.67% |
| Price to Tangible Book Value | -4.72 | -4.43 | -4.95 | -4.65 | 13.65% |
| Price to Free Cash Flow TTM | 43.75 | 171.63 | - | ||
| Enterprise Value to EBITDA | 104.98 | 63.59 | 59.49 | 52.16 | 16.55% |
| Free Cash Flow Yield | 2.3% | 0.6% | - | ||
| Return on Equity | -1.9% | -9.2% | -9.0% | -3.3% | 38.91% |
| Total Debt | $13.19B | $13.45B | $10.31B | $9.73B | -27.12% |
BAX earnings call for the period ending September 30, 2021.
BAX earnings call for the period ending June 30, 2021.
BAX earnings call for the period ending March 31, 2021.
BAX earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
